Ultragenyx Pharmaceutical | RARE - Ordinary Share Capital


Ultragenyx Pharmaceutical reported $96.44M in Ordinary Share Capital for its fiscal quarter ending in September of 2025.





Ordinary Share Capital Change Date
Acadia Pharmaceuticals USD 168.71M 104K Sep/2025
Agios Pharmaceuticals USD 58.45M 169K Dec/2025
Alnylam Pharmaceuticals USD 132.38M 585K Dec/2025
BioCryst Pharmaceuticals USD 1.9M 3K Sep/2023
BioMarin Pharmaceutical USD 192.1M 97K Sep/2025
Esperion Therapeutics USD 112K 11K Sep/2023
Immunic USD 8K 4K Jun/2024
Insmed USD 214.26M 1.67M Dec/2025
Ionis Pharmaceuticals USD 161.14M 160.98M Sep/2025
Karyopharm Therapeutics USD 13K 0 Sep/2024
Kyowa Hakko Kirin JPY 523.49M 2K Dec/2025
MacroGenics USD 63.26M 62.63M Sep/2025
Moderna USD 391M 2M Sep/2025
Neurocrine Biosciences USD 100.1M 400K Dec/2025
PTC Therapeutics USD 81.47M 1.54M Dec/2025
Puma Biotechnology USD 5K 0 Jun/2024
Regeneron Pharmaceuticals USD 105.3M 1.1M Sep/2025
Sarepta Therapeutics USD 104.77M 7.06M Sep/2025
Ultragenyx Pharmaceutical USD 96.44M 88K Sep/2025
Vertex Pharmaceuticals USD 254M 0 Dec/2025
Xoma USD 87K 1000 Jun/2024